Julian Hofmann, a seasoned pharmaceuticals expert, shares insights on AstraZeneca's potential blockbuster breast cancer drug, Enhertu, and the company’s strategic shifts. Val Cipriani, a business journalist, discusses the 'Great Wealth Transfer' and offers advice on gifting and inheritance tax, emphasizing planning for family wealth. Finally, Mark Robinson analyzes Ceres Power's disappointing interim results, Bosch’s exit, and the company's pivot toward growing tech markets, specifically data centers. Tune in for valuable insights!
